

Influenza A(H3N2) candidate vaccine viruses and potency testing reagents for vaccine development and production for the northern hemisphere 2013-14

20 February 2013 (last updated on 8 July 2013)

Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Texas/50/2012		Wild type virus	WHO CCs	
	X-223A	Classical	New York Medical College, USA	CDC, USA NYMC, USA NIBSC,UK
	X-223	Classical	New York Medical College, USA	CDC, USA NYMC, USA NIBSC,UK

Institutes contact details for candidate vaccine viruses orders/information:

CDC: xxu@cdc.gov

NYMC: doris bucher@nymc.edu

WHO CCs: http://www.who.int/influenza/gisrs laboratory/collaborating centres/list/en/

Reference antigens (freeze-dried)

	Starting materials		Pof Ac /		
Parent virus	cvv	Egg or Cell	Ref Ag / Lot #	Unitage (µgHA/mL)	Available from
*A/Texas/50/2012	NYMC X-223	Egg	13/112	74	NIBSC
	NYMC X-223A	Egg	13/116	49	NIBSC

^{*}new reference antigen

The above-listed potency testing reagents have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagents orders/information:

NIBSC: <u>standards@nibsc.org</u>

TGA: <u>influenza.reagents@tga.gov.au</u>

NIID: <u>sitamura@nih.go.jp</u>

CBER/FDA: Rajesh.Gupta@fda.hhs.gov

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/en/